Compass Therapeutics, Inc.
Compass Therapeutics, Inc. (CMPX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CMPX · as of Sep 30, 2025
Ownership Breakdown
128
Institutional Holders
▲ 22 vs Q2
$528.69M
Total Inst. Value
▲ $247.24M vs Q2
138.29M
Shares Outstanding
freeFloat 70.17%
151.05M
13F Shares Held
▲ 42.80M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CMPX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 16.81M | 12.16% | 12.16% | $58.84B | Nov 14, 2025 | ▲ 3.32M |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 15.22M | 11.01% | 11.01% | $53.27B | Nov 14, 2025 | — held |
SUVRETTA CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 14.10M | 10.20% | 10.20% | $49.35B | Nov 14, 2025 | ▲ 6.95M |
BLACKSTONE INC. biological products, (no diagnostic substances) | 9.84M | 7.12% | 7.12% | $34.44B | Nov 14, 2025 | ▼ 185.0K |
VIVO CAPITAL, LLC biological products, (no diagnostic substances) | 9.55M | 6.90% | 6.90% | $33.41B | Nov 14, 2025 | ▲ 3.50M |
ENAVATE SCIENCES GP, LLC biological products, (no diagnostic substances) | 7.79M | 5.63% | 5.63% | $27.26B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 7.37M | 5.33% | 5.33% | $25.80B | Nov 12, 2025 | ▲ 957.6K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 7.06M | 5.11% | 5.11% | $24.72B | Nov 7, 2025 | ▲ 2.21M |
ADAGE CAPITAL PARTNERS GP, L.L.C. biological products, (no diagnostic substances) | 5.19M | 3.75% | 3.75% | $18.15B | Nov 14, 2025 | ▲ 761.6K |
BIOIMPACT CAPITAL LLC biological products, (no diagnostic substances) | 5.08M | 3.67% | 3.67% | $17.77B | Nov 14, 2025 | ▼ 546.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+29.60M shares11
New Positions
first time holders11
Decreased
−2.33M shares0
Sold Out
fully exitedNet shares change (top 50)
+27.27M
+29.60M / −2.33M
Net new holders
+24
11 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CMPX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lerner Neil Chief Accounting Officer | Apr 29, 2026 | Purchase | 15,000 | $1.89 | $28.4K | 397.5K | Form 4 ↗ |
Anderman Jonathan General Counsel | Apr 29, 2026 | Purchase | 25,000 | $1.89 | $47.3K | 196.0K | Form 4 ↗ |
Anderman Jonathan General Counsel | Apr 29, 2026 | Award | 25,000 | $1.89 | $47.3K | 196.0K | Form 4 ↗ |
Lerner Neil Chief Accounting Officer | Apr 29, 2026 | Award | 15,000 | $1.89 | $28.4K | 397.5K | Form 4 ↗ |
Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Feb 8, 2026 | Tax Withhold | 36,687 | $6.52 | $239.2K | 6.60M | Form 4 ↗ |
Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Jan 9, 2026 | Tax Withhold | 46,777 | $5.35 | $250.3K | 6.64M | Form 4 ↗ |
Shin Barry CFO | Jan 2, 2026 | Award | 670,000 | $5.17 | $3.46M | 670.0K | Form 4 ↗ |
Shin Barry CFO | Jan 2, 2026 | Award | 125,000 | $5.17 | $646.3K | 525.0K | Form 4 ↗ |
Sirard Cynthia Chief Medical Officer | Jan 2, 2026 | Award | 1,000,000 | $5.17 | $5.17M | 1.00M | Form 4 ↗ |
Schuetz Thomas J. CEO | Jan 2, 2026 | Award | 250,000 | $5.17 | $1.29M | 6.69M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Compass Therapeutics, Inc. (CMPX) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 29.83%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Compass Therapeutics, Inc. is TANG CAPITAL MANAGEMENT LLC, holding approximately 16.81 million shares — equal to 12.16% of outstanding shares — as of September 30, 2025.
A total of 128 institutional investors currently hold CMPX stock, with a combined institutional value of approximately $528,694,354 as of the most recent 13F filing period.
Frequently asked questions
CMPX ownershipCompass Therapeutics, Inc. (CMPX) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is TANG CAPITAL MANAGEMENT LLC with a 12.16% stake. Company insiders hold 29.83%. Data sourced from SEC Form 13F as of September 30, 2025.